Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2013) 1 PP425 | DOI: 10.1530/boneabs.1.PP425

ECTS2013 Poster Presentations Osteoporosis: treatment (64 abstracts)

Evaluation with densitometry of patients with breast cancer and low bone mineral density after 2 years of treatment

Sonia Muñoz Gil 1 , Tomás Mut Dólera 2 , Belén C Garrido López 1 , M D Torregrosa Maicas 3 , R Gironés Sarrió 3 , P López Tendero 3 , M D García Armario 4 & Pascual Muñoz Mira 1


1Hospital de Manises, Manises, Valencia, Spain; 2Hospital de La Ribera, Alzira, Valencia, Spain; 3Hospital Lluïs Alcanyis, Xàtiva, Valencia, Spain; 4Hospital General de Ontinyent, Ontinyent, Valencia, Spain.


Aim: Evaluate the differences with densitometry after 2-year treatment in patients with breast cancer and LBMD.

Materials and methods: A 2 year duration longitudinal study was done in patients diagnosed with breast cancer sent to the Rheumatology Osteoporosis Unit in Hospital d’Ontinyent, who required supplements of calcium and vitamin D+bisphosphonates after a risk fracture study. Socio-demographic data, breast tumor characteristics, risk factors for osteoporosis and fragile fractures, definite diagnosis and the treatment initiated were registered. Differences between mean values obtained in BMD of lumbar, total femoral, and femoral neck, were evaluated with student’s t-test study.

Results: 61 patients were studied, with an average age of 59 years old (37–79 years). All had unilateral breast cancer, while none had metastases. Treatments received were: radical mastectomy (56%), radiotherapy (64%), chemotherapy (71%), hormonotherapy (30%), tamoxifen (41%), GnRH analogues (13%), and aromatase inhibitors (90%). High-risk osteoporosis was diagnosed in 6 patients, osteoporosis in 19 patients and osteopenia in 26 patients. In spinal X-rays, 26 patients had >1 vertebral collapse and 4 of them >1 vertebral fracture. Treatment with supplements of calcium and vitamin D was initiated in 85.2%, and bisphosphonates (oral or i.v.) in 41 patients, as follow: ibandronate (15), risedronate (16), alendronate (8), and zoledronate (2).

After a 2-year follow-up, only one patient had developed metastases, 75.4% continued with aromatase inhibitors and only two had abandoned treatment. None suffered new vertebral collapse or fracture, only one suffered from other fractures.

Conclusions: Patients with breast cancer that require initiating treatment for fragile risk fracture present good treatment compliance. Treatment including supplements of calcium and vitamin D and bisphosphonates during two years improves the mineral bone density, finding statistically significative differences in femoral neck (BMD, T-score, Z-score) and in all localizations (lumbar, femoral neck and total femoral) while using Z-score.

Volume 1

European Calcified Tissue Society Congress 2013

Lisbon, Portugal
18 May 2013 - 22 May 2013

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.